CleneCLNN
CLNN
About: Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
Employees: 85
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
85% more capital invested
Capital invested by funds: $2.53M [Q2] → $4.66M (+$2.14M) [Q3]
74% more call options, than puts
Call options by funds: $282K | Put options by funds: $162K
10.17% more ownership
Funds ownership: 5.52% [Q2] → 15.69% (+10.17%) [Q3]
46% less funds holding
Funds holding: 37 [Q2] → 20 (-17) [Q3]
71% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 24
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 13
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
360%
upside
Avg. target
$49
876%
upside
High target
$84
1,580%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 27% 1-year accuracy 41 / 153 met price target | 360%upside $23 | Buy Maintained | 19 Dec 2024 |
Benchmark Bruce Jackson 48% 1-year accuracy 26 / 54 met price target | 1,580%upside $84 | Buy Maintained | 22 Nov 2024 |
Canaccord Genuity Sumant Kulkarni 25% 1-year accuracy 8 / 32 met price target | 1,560%upside $83 | Buy Maintained | 14 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 22% 1-year accuracy 86 / 386 met price target | 520%upside $31 | Buy Reiterated | 14 Nov 2024 |
EF Hutton Jason Kolbert 27% 1-year accuracy 41 / 153 met price target | 360%upside $23 | Buy Maintained | 24 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it recently received written guidance from the Division of Neurology 1 (DN1), of the U.S. Food and Drug Administration (FDA) regarding a potential accelerated approval pathway for CNM-Au8 ® in ALS.
Negative
Zacks Investment Research
1 month ago
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to loss of $0.40 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that on September 30, 2024 it entered into a securities purchase agreement with a healthcare focused institutional investor (“Healthcare Investor”) for the issuance and sale of 742,626 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, Clene also agreed to issue to the Healthcare Investor warrants to purchase up to 742,626 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one warrant to purchase one share of common stock at a combined purchase price of $4.713. The warrants have an exercise price of $4.82 per share, are immediately exercisable and will expire five years following the date of issuance.
Neutral
GlobeNewsWire
3 months ago
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Food and Drug Administration (FDA) before the end of November 2024 to discuss CNM-Au8 development for ALS.
Neutral
GlobeNewsWire
3 months ago
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference and host 1x1 investor meetings.
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet
The consensus price target hints at an 873.5% upside potential for Clene (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
4 months ago
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade
The mean of analysts' price targets for Clene (CLNN) points to a 976.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
4 months ago
IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.
LOS ANGELES, Aug. 08, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
Negative
Zacks Investment Research
4 months ago
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.60. This compares to loss of $2.40 per share a year ago.
Neutral
GlobeNewsWire
4 months ago
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its second quarter 2024 financial results and provided recent updates on its CNM-Au8® programs.
Charts implemented using Lightweight Charts™